OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

NCT Number	NCT05333328
Lead Sponsor	Gangnam Severance Hospital Collaborators: Seoul National University
Conditions	Breast Cancer, Estrogen Receptor Positive Tumor, HER2-negative Breast Cancer, Premenopausal Breast Cancer, Node-positive Breast Cancer
Enrollment	418 participants
Start Date	2023-02-06
Primary Completion	2031-01 (estimated)
Study Completion	2033-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-22